Trek Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Trek Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-279	Closed	-$216K	–	550
2026 Q1	$216K	Buy	+279	New	+$214K	0.01%	441

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Trek Financial's REGN Position: Q2 2026 in Review

Trek Financial sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 279 shares — an estimated $216K sold.

Trek Financial first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $216K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Trek Financial reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Trek Financial sold 279 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
Trek Financial first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Trek Financial's Regeneron Pharmaceuticals position peaked at $216K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Trek Financial's 13F filing for Q2 2026, filed 13 Aug 2026.